I'm sure that Dr Coles won't miss this opportunity to make positive PR again!
1. The Kypro sales are up more than analyst expected
2. the usage is goes toward first line treatment.
3. Nevaxtar sales are flat- up in Asia and down in the rest of the world.
4. No names or number dropping regarding buyout- "we are in contact with interested parties and expect to hear from them soon." He'll sound very optimistic.
5. The s/p will go up by 4-5 points.
Kot, management's outright rejection of the $120 Amgen offer as not being reflective of Onyx's true value and its readiness to open the company's books to serious bidders are probably signalling strong Kyprolis sales and that the phase II/III studies are going well.
John, I don't think that potential buyers checking on sales...In 2 days it will become public knowledge...I think they're more interested in some trial progress/results that are still not finished and not quantified, but able to provide some anecdotical evidence for that or other drug performance. They also might be very interested in details of agreement with Bayer....
One wonders if they will really "open the books" to potential buyers - at least as regards quarterly sales - until after earnings. It would seem questionable to disclose information to your competitors and their bankers while withholding it from your own shareholders. But I agree that Coles, whom I think some have underrated, is probably playing a strong hand.